5,401 Shares in Halozyme Therapeutics, Inc. $HALO Bought by Pacific Wealth Management

Pacific Wealth Management acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, HoldingsChannel reports. The institutional investor acquired 5,401 shares of the biopharmaceutical company’s stock, valued at approximately $423,000. Halozyme Therapeutics accounts for 0.2% of Pacific Wealth Management’s portfolio, making the stock its 11th largest position.

Other institutional investors have also recently added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC raised its holdings in shares of Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 124 shares during the period. Abel Hall LLC boosted its holdings in shares of Halozyme Therapeutics by 4.2% in the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock valued at $216,000 after buying an additional 129 shares during the period. StoneX Group Inc. grew its position in shares of Halozyme Therapeutics by 3.8% during the 4th quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 132 shares during the last quarter. Twin Capital Management Inc. grew its position in shares of Halozyme Therapeutics by 1.4% during the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 161 shares during the last quarter. Finally, Coldstream Capital Management Inc. raised its stake in Halozyme Therapeutics by 1.9% during the third quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock worth $654,000 after acquiring an additional 165 shares during the period. Institutional investors own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of recent research reports. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. TD Cowen upped their target price on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a report on Friday, August 7th. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. HC Wainwright increased their target price on Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, Weiss Ratings cut Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $91.20.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $104.89 on Wednesday. The firm’s 50 day moving average is $80.97 and its two-hundred day moving average is $73.02. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $105.11. The firm has a market capitalization of $11.91 billion, a P/E ratio of 31.31, a PEG ratio of 0.40 and a beta of 0.85. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. During the same quarter in the previous year, the company posted $1.54 earnings per share. The business’s revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Analysts anticipate that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 1,923 shares of the firm’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $79.77, for a total transaction of $153,397.71. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $61,245,810.60. This trade represents a 0.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director directly owned 14,462 shares in the company, valued at $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 44,103 shares of company stock valued at $3,142,896 in the last quarter. Corporate insiders own 2.50% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.